StreetInsider.com News Articles

Sana Biotechnology to Present at September 2026 Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.

Sana will present at the 2026 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Tuesday, September 8, 2026.
Sana will present at Citi’s 2026 Biopharma Back-to-School Conference at 1:40 p.m. ET on Thursday, September 10, 2026.
Sana will present at the Morgan Stanley 24^th Annual Global Healthcare Conference at 4:50

Sana Biotechnology to Present at September 2026 Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

Sana will present at the 2026 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Tuesday, September 8, 2026.
Sana will present at Citi’s 2026 Biopharma Back-to-School Conference at 1:40 p.m. ET on Thursday, September 10, 2026.
Sana will present at the Morgan Stanley 24^th Annual Global Healthcare Conference at 4:50

Form 4 Sana Biotechnology, Inc. For: Aug 26 Filed by: PATEL DHAVALKUMAR DHIRAJLAL

Thu, 27 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260827/26990331.html

Form 4 Sana Biotechnology, Inc. For: Aug 26 Filed by: PATEL DHAVALKUMAR DHIRAJLAL

Thu, 27 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260827/26990331.html

TD Cowen Assumes Sana Biotechnology (SANA) at Buy

Sat, 22 Aug 2026 07:55:11 -0400

TD Cowen analyst Phil Nadeau assumes coverage on Sana Biotechnology (NASDAQ: SANA) with a Buy rating.

For an analyst ratings summary and ratings history on Sana Biotechnology click here. For more ratings news on Sana Biotechnology click here.

Shares of Sana Biotechnology closed at $3.91 yesterday.

Form SCHEDULE 13G/A Sana Biotechnology, Inc. Filed by: ARCH Venture Fund IX, L.P.

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930208.html

Form SCHEDULE 13G/A Sana Biotechnology, Inc. Filed by: ARCH Venture Fund IX, L.P.

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930208.html

Sana Biotechnology (SANA) PT Lowered to $6 at BofA Securities

Fri, 14 Aug 2026 05:18:47 -0400

BofA Securities analyst Alex Stranahan lowered the price target on Sana Biotechnology (NASDAQ: SANA) to $6.00 (from $7.00) while maintaining a Buy rating.

Sana Biotechnology, Inc. (SANA) Tops Q2 EPS by 2c

Mon, 10 Aug 2026 17:03:50 -0400

Sana Biotechnology, Inc. (NASDAQ: SANA) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Sana Biotechnology, Inc. (SANA) click here.

Form 10-Q Sana Biotechnology, Inc. For: Jun 30

Mon, 10 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260810/26898016.html

Form 10-Q Sana Biotechnology, Inc. For: Jun 30

Mon, 10 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260810/26898016.html

Form 8-K Sana Biotechnology, Inc. For: Aug 10

Mon, 10 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260810/26897944.html

Form 8-K Sana Biotechnology, Inc. For: Aug 10

Mon, 10 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260810/26897944.html

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Mon, 10 Aug 2026 16:05:00 -0400

Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness

Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma and generating initial clinical data, including manufacturing and clinical trial readiness

Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet cell transplantation with UP421 without immunosuppression in type 1 diabetes

Announced upcoming symposium presentation highlighting UP421 clinical data at the European Association for the Study of Diabetes (EASD) Annual

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Mon, 10 Aug 2026 16:05:00 -0400

Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness

Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma and generating initial clinical data, including manufacturing and clinical trial readiness

Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet cell transplantation with UP421 without immunosuppression in type 1 diabetes

Announced upcoming symposium presentation highlighting UP421 clinical data at the European Association for the Study of Diabetes (EASD) Annual

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplanta

Mon, 13 Jul 2026 08:00:00 -0400

Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025

Seminal Study Successfully Achieved Primary and Secondary Endpoints, Demonstrating that Hypoimmune (HIP)-Modified Islets are Safe, Evade Detection by the Immune System, Survive, and Function Long-Term and Continue to Produce Insulin in the Patient for Over One Year Following Administration Without Immunosuppression

Sana Expects to File Investigational New Drug (IND) Application and Initiate Phase 1/2 Trial as Early as This Year for SC451, a HIP-Modified, Stem Cell-Derived

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplanta

Mon, 13 Jul 2026 08:00:00 -0400

Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025

Seminal Study Successfully Achieved Primary and Secondary Endpoints, Demonstrating that Hypoimmune (HIP)-Modified Islets are Safe, Evade Detection by the Immune System, Survive, and Function Long-Term and Continue to Produce Insulin in the Patient for Over One Year Following Administration Without Immunosuppression

Sana Expects to File Investigational New Drug (IND) Application and Initiate Phase 1/2 Trial as Early as This Year for SC451, a HIP-Modified, Stem Cell-Derived

Form 4 Sana Biotechnology, Inc. For: Jul 06 Filed by: Bishop Hans Edgar

Tue, 07 Jul 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260707/26742189.html

Form 4 Sana Biotechnology, Inc. For: Jul 06 Filed by: Bishop Hans Edgar

Tue, 07 Jul 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260707/26742189.html

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

Wed, 01 Jul 2026 09:00:00 -0400

SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform (HIP) technology, into a patient with type 1 diabetes without any immunosuppression. The symposium will be held at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 taking place from September 28 - October 2, 2026 in Milan, Italy.

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

Wed, 01 Jul 2026 09:00:00 -0400

SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform (HIP) technology, into a patient with type 1 diabetes without any immunosuppression. The symposium will be held at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 taking place from September 28 - October 2, 2026 in Milan, Italy.

Sana Biotechnology (SANA) Reiterated at Market Outperform by Citizens

Wed, 01 Jul 2026 04:54:26 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $8.00 price target on Sana Biotechnology (NASDAQ: SANA).
The analyst commented, " File IND for SG293 (CD8/CD19 In Vivo CAR T program). SG293 is the first candidate from Sana's fusogenbased in vivo CAR-T platform. It uses a CD8-targeted virus-like particle to deliver a CD19 CAR specifically into CD8+ T cells, where it integrates into the cell’s DNA for durable expression. The design is also intended to allow transduction of resting T cells, reduce anti-CAR immunogenicity, and limit off-target delivery. Preclinical NHP data presented at ASGCT 2026 showed cell-specific delivery, dose-dependent CAR-T

Form 4 Sana Biotechnology, Inc. For: Jun 04 Filed by: Yang Patrick Y

Fri, 05 Jun 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260605/26611832.html

Form 4 Sana Biotechnology, Inc. For: Jun 04 Filed by: Yang Patrick Y

Fri, 05 Jun 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260605/26611832.html

Form 4 Sana Biotechnology, Inc. For: Jun 04 Filed by: Rosiello Robert L.

Fri, 05 Jun 2026 16:41:00 -0400
si-local-file:///var/storage/secattach/20260605/26611815.html